OAK RIDGE, TN — January 23, 2026 — Leads & Copy — Daxor Corporation (NasdaqCM: DXR) has entered into a definitive agreement with fundamental investors for the purchase and sale of 765,958 shares of its common stock at $11.75 per share.
The offering is expected to close around January 26, 2026, pending customary closing conditions.
The gross proceeds for Daxor are anticipated to be approximately $9 million before deducting placement agent’s fees and other offering expenses. The company plans to use the net proceeds for general corporate purposes, including working capital.
Lake Street Capital Markets, LLC is the exclusive placement agent for the offering.
A registration statement on Form N-2 (File Nos. 333-281622 and 881-22684) related to the shares was originally filed with the SEC on August 16, 2024, and declared effective on January 20, 2026. The offering is being made via a prospectus supplement and accompanying prospectus that form part of the registration statement. The final prospectus supplement and accompanying prospectus will be filed with the SEC and available on its website.
Electronic copies of the final prospectus supplement and accompanying prospectus, when filed, can be obtained on the SEC’s website or by contacting Lake Street Capital Markets, LLC.
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities. It also does not represent a sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful, prior to registration or qualification under the securities laws of that state or jurisdiction.
Daxor Corporation is focused on precisely measuring blood volume to improve patient care and hospital efficiency. Its FDA-cleared Blood Volume Analysis (BVA) diagnostic provides real-time data to clinicians, enabling individualized treatment decisions.
Daxor operates a U.S.-based, 20,000-square-foot manufacturing facility.
Source: Daxor Corporation
